Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 7.9% in November

Keros Therapeutics, Inc. (NASDAQ:KROS) saw a significant decline in short interest in November. As of November 15th, there was short interest totalling 2,220,000 shares, a decline of 7.9% from the October 31st total of 2,410,000 shares. Based on an average daily volume of 370,500 shares, the days-to-cover ratio is presently 6.0 days.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $62.28 on Wednesday. The business has a fifty day moving average of $59.67 and a 200 day moving average of $52.37. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -11.95 and a beta of 1.20. Keros Therapeutics has a 1 year low of $27.31 and a 1 year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million for the quarter. During the same period last year, the business earned ($1.33) earnings per share. The firm’s revenue for the quarter was up 4750.0% on a year-over-year basis. As a group, equities research analysts expect that Keros Therapeutics will post -5.28 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on KROS. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Guggenheim started coverage on Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company. Finally, Bank of America decreased their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $88.89.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in KROS. KBC Group NV lifted its holdings in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares during the period. Values First Advisors Inc. purchased a new position in Keros Therapeutics in the third quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics in the second quarter valued at $128,000. Finally, LMR Partners LLP acquired a new position in shares of Keros Therapeutics in the third quarter worth about $213,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.